A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants
An Investigator/Subject Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of RO7034067 in Healthy Japanese Subjects
Sponsor: Hoffmann-La Roche
This PHASE1 trial investigates Healthy Volunteers and is currently completed. Hoffmann-La Roche leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
May 2017 — Dec 2017 [monthly]
Recruiting PHASE1
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE1
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Mar 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .